Rhuematoid Arthritis Drugs Market 2028 by Drug Class, Route of Administration, Sales Channel and Geography | The Insight Partners

    Rhuematoid Arthritis Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis By Drug Class ( Disease-modifying Anti-rheumatic Drugs (DMARDs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Others ); Route of Administration ( Oral, Parenteral ); Sales Channel ( Prescription-based Drugs, Over-the-counter Drugs ) and Geography

    Report Code: TIPRE00016376 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

    MARKET INTRODUCTION

    Rheumatoid arthritis (RA) is a progressive inflammatory disease that affects the joints. It gets worse over time unless the inflammation is stopped or slowed. Only in very rare cases does rheumatoid arthritis go into remission without treatment.

    MARKET DYNAMICS

    The rheumatoid arthritis drugs market is driving due to the factors such as rising prevalence of rheumatoid arthritis, increasing number of patent expiry and advances and innovation in biological sciences. In addition, development and launch of new and innovative biosimilars and generic drugs are likely to offer growth opportunities for market players.

    MARKET SCOPE

    The "Rheumatoid Arthritis Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of rheumatoid arthritis drugs market with detailed market segmentation by drug class, route of administration, and sales channel. The rheumatoid arthritis drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in rheumatoid arthritis drugs market and offers key trends and opportunities in the market.

    MARKET SEGMENTATION

    The rheumatoid arthritis drugs market is segmented on the basis of drug class, route of administration, and sales channel. Based on drug class, the market is segmented as disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. On the basis of route of administration, the market is segmented into oral and parenteral. Based on sales channel, the market is segmented into prescription-based drugs and over-the-counter drugs.

    REGIONAL FRAMEWORK

    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the rheumatoid arthritis drugs market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The rheumatoid arthritis drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

    The report analyzes factors affecting rheumatoid arthritis drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the rheumatoid arthritis drugs market in these regions.



    Get more information on this report :

    MARKET PLAYERS

    The report covers key developments in the rheumatoid arthritis drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from rheumatoid arthritis drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for rheumatoid arthritis drugs in the global market. Below mentioned is the list of few companies engaged in the rheumatoid arthritis drugs market.

    The report also includes the profiles of key players in rheumatoid arthritis drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.

    - AbbVie Inc.
    - Amgen Inc.
    - Bristol-Myers Squibb Company
    - Eli Lilly and Company
    - F. Hoffmann-La Roche Ltd
    - Johnson and Johnson Services, Inc.
    - Merck KGaA
    - Novartis AG
    - Pfizer, Inc.
    - UCB S.A.

    The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.



    Get more information on this report :

    TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Rheumatoid Arthritis Drugs Market - By Drug Class
    1.3.2 Rheumatoid Arthritis Drugs Market - By Route of Administration
    1.3.3 Rheumatoid Arthritis Drugs Market - By Sales Channel
    1.3.4 Rheumatoid Arthritis Drugs Market - By Region
    1.3.4.1 By Country
    2. KEY TAKEAWAYS
    3. RESEARCH METHODOLOGY
    4. RHEUMATOID ARTHRITIS DRUGS MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PEST ANALYSIS
    4.2.1 North America - Pest Analysis
    4.2.2 Europe - Pest Analysis
    4.2.3 Asia-Pacific - Pest Analysis
    4.2.4 Middle East and Africa - Pest Analysis
    4.2.5 South and Central America - Pest Analysis
    4.3. EXPERT OPINIONS
    5. RHEUMATOID ARTHRITIS DRUGS MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
    6. RHEUMATOID ARTHRITIS DRUGS MARKET - GLOBAL MARKET ANALYSIS
    6.1. RHEUMATOID ARTHRITIS DRUGS - GLOBAL MARKET OVERVIEW
    6.2. RHEUMATOID ARTHRITIS DRUGS - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE
    7. RHEUMATOID ARTHRITIS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
    7.1. OVERVIEW
    7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
    7.3. DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)
    7.3.1. Overview
    7.3.2. Disease-modifying Anti-rheumatic Drugs (DMARDs) Market Forecast and Analysis
    7.4. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
    7.4.1. Overview
    7.4.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Forecast and Analysis
    7.5. CORTICOSTEROIDS
    7.5.1. Overview
    7.5.2. Corticosteroids Market Forecast and Analysis
    7.6. URIC ACID DRUGS
    7.6.1. Overview
    7.6.2. Uric Acid Drugs Market Forecast and Analysis
    7.7. OTHERS
    7.7.1. Overview
    7.7.2. Others Market Forecast and Analysis
    8. RHEUMATOID ARTHRITIS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
    8.1. OVERVIEW
    8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
    8.3. ORAL
    8.3.1. Overview
    8.3.2. Oral Market Forecast and Analysis
    8.4. PARENTERAL
    8.4.1. Overview
    8.4.2. Parenteral Market Forecast and Analysis
    9. RHEUMATOID ARTHRITIS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - SALES CHANNEL
    9.1. OVERVIEW
    9.2. SALES CHANNEL MARKET FORECASTS AND ANALYSIS
    9.3. PRESCRIPTION-BASED DRUGS
    9.3.1. Overview
    9.3.2. Prescription-based Drugs Market Forecast and Analysis
    9.4. OVER-THE-COUNTER DRUGS
    9.4.1. Overview
    9.4.2. Over-the-counter Drugs Market Forecast and Analysis
    10. RHEUMATOID ARTHRITIS DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    10.1. NORTH AMERICA
    10.1.1 North America Rheumatoid Arthritis Drugs Market Overview
    10.1.2 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis
    10.1.3 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Drug Class
    10.1.4 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
    10.1.5 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Sales Channel
    10.1.6 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
    10.1.6.1 United States Rheumatoid Arthritis Drugs Market
    10.1.6.1.1 United States Rheumatoid Arthritis Drugs Market by Drug Class
    10.1.6.1.2 United States Rheumatoid Arthritis Drugs Market by Route of Administration
    10.1.6.1.3 United States Rheumatoid Arthritis Drugs Market by Sales Channel
    10.1.6.2 Canada Rheumatoid Arthritis Drugs Market
    10.1.6.2.1 Canada Rheumatoid Arthritis Drugs Market by Drug Class
    10.1.6.2.2 Canada Rheumatoid Arthritis Drugs Market by Route of Administration
    10.1.6.2.3 Canada Rheumatoid Arthritis Drugs Market by Sales Channel
    10.1.6.3 Mexico Rheumatoid Arthritis Drugs Market
    10.1.6.3.1 Mexico Rheumatoid Arthritis Drugs Market by Drug Class
    10.1.6.3.2 Mexico Rheumatoid Arthritis Drugs Market by Route of Administration
    10.1.6.3.3 Mexico Rheumatoid Arthritis Drugs Market by Sales Channel
    10.2. EUROPE
    10.2.1 Europe Rheumatoid Arthritis Drugs Market Overview
    10.2.2 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis
    10.2.3 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Drug Class
    10.2.4 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
    10.2.5 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Sales Channel
    10.2.6 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
    10.2.6.1 Germany Rheumatoid Arthritis Drugs Market
    10.2.6.1.1 Germany Rheumatoid Arthritis Drugs Market by Drug Class
    10.2.6.1.2 Germany Rheumatoid Arthritis Drugs Market by Route of Administration
    10.2.6.1.3 Germany Rheumatoid Arthritis Drugs Market by Sales Channel
    10.2.6.2 France Rheumatoid Arthritis Drugs Market
    10.2.6.2.1 France Rheumatoid Arthritis Drugs Market by Drug Class
    10.2.6.2.2 France Rheumatoid Arthritis Drugs Market by Route of Administration
    10.2.6.2.3 France Rheumatoid Arthritis Drugs Market by Sales Channel
    10.2.6.3 Italy Rheumatoid Arthritis Drugs Market
    10.2.6.3.1 Italy Rheumatoid Arthritis Drugs Market by Drug Class
    10.2.6.3.2 Italy Rheumatoid Arthritis Drugs Market by Route of Administration
    10.2.6.3.3 Italy Rheumatoid Arthritis Drugs Market by Sales Channel
    10.2.6.4 Spain Rheumatoid Arthritis Drugs Market
    10.2.6.4.1 Spain Rheumatoid Arthritis Drugs Market by Drug Class
    10.2.6.4.2 Spain Rheumatoid Arthritis Drugs Market by Route of Administration
    10.2.6.4.3 Spain Rheumatoid Arthritis Drugs Market by Sales Channel
    10.2.6.5 United Kingdom Rheumatoid Arthritis Drugs Market
    10.2.6.5.1 United Kingdom Rheumatoid Arthritis Drugs Market by Drug Class
    10.2.6.5.2 United Kingdom Rheumatoid Arthritis Drugs Market by Route of Administration
    10.2.6.5.3 United Kingdom Rheumatoid Arthritis Drugs Market by Sales Channel
    10.2.6.6 Rest of Europe Rheumatoid Arthritis Drugs Market
    10.2.6.6.1 Rest of Europe Rheumatoid Arthritis Drugs Market by Drug Class
    10.2.6.6.2 Rest of Europe Rheumatoid Arthritis Drugs Market by Route of Administration
    10.2.6.6.3 Rest of Europe Rheumatoid Arthritis Drugs Market by Sales Channel
    10.3. ASIA-PACIFIC
    10.3.1 Asia-Pacific Rheumatoid Arthritis Drugs Market Overview
    10.3.2 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis
    10.3.3 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Drug Class
    10.3.4 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
    10.3.5 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Sales Channel
    10.3.6 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
    10.3.6.1 Australia Rheumatoid Arthritis Drugs Market
    10.3.6.1.1 Australia Rheumatoid Arthritis Drugs Market by Drug Class
    10.3.6.1.2 Australia Rheumatoid Arthritis Drugs Market by Route of Administration
    10.3.6.1.3 Australia Rheumatoid Arthritis Drugs Market by Sales Channel
    10.3.6.2 China Rheumatoid Arthritis Drugs Market
    10.3.6.2.1 China Rheumatoid Arthritis Drugs Market by Drug Class
    10.3.6.2.2 China Rheumatoid Arthritis Drugs Market by Route of Administration
    10.3.6.2.3 China Rheumatoid Arthritis Drugs Market by Sales Channel
    10.3.6.3 India Rheumatoid Arthritis Drugs Market
    10.3.6.3.1 India Rheumatoid Arthritis Drugs Market by Drug Class
    10.3.6.3.2 India Rheumatoid Arthritis Drugs Market by Route of Administration
    10.3.6.3.3 India Rheumatoid Arthritis Drugs Market by Sales Channel
    10.3.6.4 Japan Rheumatoid Arthritis Drugs Market
    10.3.6.4.1 Japan Rheumatoid Arthritis Drugs Market by Drug Class
    10.3.6.4.2 Japan Rheumatoid Arthritis Drugs Market by Route of Administration
    10.3.6.4.3 Japan Rheumatoid Arthritis Drugs Market by Sales Channel
    10.3.6.5 South Korea Rheumatoid Arthritis Drugs Market
    10.3.6.5.1 South Korea Rheumatoid Arthritis Drugs Market by Drug Class
    10.3.6.5.2 South Korea Rheumatoid Arthritis Drugs Market by Route of Administration
    10.3.6.5.3 South Korea Rheumatoid Arthritis Drugs Market by Sales Channel
    10.3.6.6 Rest of Asia-Pacific Rheumatoid Arthritis Drugs Market
    10.3.6.6.1 Rest of Asia-Pacific Rheumatoid Arthritis Drugs Market by Drug Class
    10.3.6.6.2 Rest of Asia-Pacific Rheumatoid Arthritis Drugs Market by Route of Administration
    10.3.6.6.3 Rest of Asia-Pacific Rheumatoid Arthritis Drugs Market by Sales Channel
    10.4. MIDDLE EAST AND AFRICA
    10.4.1 Middle East and Africa Rheumatoid Arthritis Drugs Market Overview
    10.4.2 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis
    10.4.3 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Drug Class
    10.4.4 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
    10.4.5 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Sales Channel
    10.4.6 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
    10.4.6.1 South Africa Rheumatoid Arthritis Drugs Market
    10.4.6.1.1 South Africa Rheumatoid Arthritis Drugs Market by Drug Class
    10.4.6.1.2 South Africa Rheumatoid Arthritis Drugs Market by Route of Administration
    10.4.6.1.3 South Africa Rheumatoid Arthritis Drugs Market by Sales Channel
    10.4.6.2 Saudi Arabia Rheumatoid Arthritis Drugs Market
    10.4.6.2.1 Saudi Arabia Rheumatoid Arthritis Drugs Market by Drug Class
    10.4.6.2.2 Saudi Arabia Rheumatoid Arthritis Drugs Market by Route of Administration
    10.4.6.2.3 Saudi Arabia Rheumatoid Arthritis Drugs Market by Sales Channel
    10.4.6.3 U.A.E Rheumatoid Arthritis Drugs Market
    10.4.6.3.1 U.A.E Rheumatoid Arthritis Drugs Market by Drug Class
    10.4.6.3.2 U.A.E Rheumatoid Arthritis Drugs Market by Route of Administration
    10.4.6.3.3 U.A.E Rheumatoid Arthritis Drugs Market by Sales Channel
    10.4.6.4 Rest of Middle East and Africa Rheumatoid Arthritis Drugs Market
    10.4.6.4.1 Rest of Middle East and Africa Rheumatoid Arthritis Drugs Market by Drug Class
    10.4.6.4.2 Rest of Middle East and Africa Rheumatoid Arthritis Drugs Market by Route of Administration
    10.4.6.4.3 Rest of Middle East and Africa Rheumatoid Arthritis Drugs Market by Sales Channel
    10.5. SOUTH AND CENTRAL AMERICA
    10.5.1 South and Central America Rheumatoid Arthritis Drugs Market Overview
    10.5.2 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis
    10.5.3 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Drug Class
    10.5.4 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
    10.5.5 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Sales Channel
    10.5.6 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
    10.5.6.1 Brazil Rheumatoid Arthritis Drugs Market
    10.5.6.1.1 Brazil Rheumatoid Arthritis Drugs Market by Drug Class
    10.5.6.1.2 Brazil Rheumatoid Arthritis Drugs Market by Route of Administration
    10.5.6.1.3 Brazil Rheumatoid Arthritis Drugs Market by Sales Channel
    10.5.6.2 Argentina Rheumatoid Arthritis Drugs Market
    10.5.6.2.1 Argentina Rheumatoid Arthritis Drugs Market by Drug Class
    10.5.6.2.2 Argentina Rheumatoid Arthritis Drugs Market by Route of Administration
    10.5.6.2.3 Argentina Rheumatoid Arthritis Drugs Market by Sales Channel
    10.5.6.3 Rest of South and Central America Rheumatoid Arthritis Drugs Market
    10.5.6.3.1 Rest of South and Central America Rheumatoid Arthritis Drugs Market by Drug Class
    10.5.6.3.2 Rest of South and Central America Rheumatoid Arthritis Drugs Market by Route of Administration
    10.5.6.3.3 Rest of South and Central America Rheumatoid Arthritis Drugs Market by Sales Channel
    11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET
    11.1 North America
    11.2 Europe
    11.3 Asia-Pacific
    11.4 Middle East and Africa
    11.5 South and Central America
    12. INDUSTRY LANDSCAPE
    12.1. MERGERS AND ACQUISITIONS
    12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    12.3. NEW PRODUCT LAUNCHES
    12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
    13. RHEUMATOID ARTHRITIS DRUGS MARKET, KEY COMPANY PROFILES
    13.1. ABBVIE INC.
    13.1.1. Key Facts
    13.1.2. Business Description
    13.1.3. Products and Services
    13.1.4. Financial Overview
    13.1.5. SWOT Analysis
    13.1.6. Key Developments
    13.2. AMGEN INC.
    13.2.1. Key Facts
    13.2.2. Business Description
    13.2.3. Products and Services
    13.2.4. Financial Overview
    13.2.5. SWOT Analysis
    13.2.6. Key Developments
    13.3. BRISTOL-MYERS SQUIBB COMPANY
    13.3.1. Key Facts
    13.3.2. Business Description
    13.3.3. Products and Services
    13.3.4. Financial Overview
    13.3.5. SWOT Analysis
    13.3.6. Key Developments
    13.4. ELI LILLY AND COMPANY
    13.4.1. Key Facts
    13.4.2. Business Description
    13.4.3. Products and Services
    13.4.4. Financial Overview
    13.4.5. SWOT Analysis
    13.4.6. Key Developments
    13.5. F. HOFFMANN-LA ROCHE LTD
    13.5.1. Key Facts
    13.5.2. Business Description
    13.5.3. Products and Services
    13.5.4. Financial Overview
    13.5.5. SWOT Analysis
    13.5.6. Key Developments
    13.6. JOHNSON AND JOHNSON SERVICES, INC.
    13.6.1. Key Facts
    13.6.2. Business Description
    13.6.3. Products and Services
    13.6.4. Financial Overview
    13.6.5. SWOT Analysis
    13.6.6. Key Developments
    13.7. MERCK KGAA
    13.7.1. Key Facts
    13.7.2. Business Description
    13.7.3. Products and Services
    13.7.4. Financial Overview
    13.7.5. SWOT Analysis
    13.7.6. Key Developments
    13.8. NOVARTIS AG
    13.8.1. Key Facts
    13.8.2. Business Description
    13.8.3. Products and Services
    13.8.4. Financial Overview
    13.8.5. SWOT Analysis
    13.8.6. Key Developments
    13.9. PFIZER, INC.
    13.9.1. Key Facts
    13.9.2. Business Description
    13.9.3. Products and Services
    13.9.4. Financial Overview
    13.9.5. SWOT Analysis
    13.9.6. Key Developments
    13.10. UCB S.A.
    13.10.1. Key Facts
    13.10.2. Business Description
    13.10.3. Products and Services
    13.10.4. Financial Overview
    13.10.5. SWOT Analysis
    13.10.6. Key Developments
    14. APPENDIX
    14.1. ABOUT THE INSIGHT PARTNERS
    14.2. GLOSSARY OF TERMS
    The List of Companies

    1. AbbVie Inc.
    2. Amgen Inc.
    3. Bristol-Myers Squibb Company
    4. Eli Lilly and Company
    5. F. Hoffmann-La Roche Ltd
    6. Johnson and Johnson Services, Inc.
    7. Merck KGaA
    8. Novartis AG
    9. Pfizer, Inc.
    10. UCB S.A
    TIPRE00016376
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Pricing
    • $3000
    • $4550
    • $6550
    • $8550

        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount   Speak to Analyst